Age Related Macular Degeneration Market to Grow Positively at a Paltry CAGR During the Study Period (2020-2034), Assesses DelveInsight | Companies- Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., Regenxbio, Alexion Pharma

DelveInsight's "Age Related Macular Degeneration - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Age Related Macular Degeneration market share of the individual therapies, current and forecasted Age Related Macular Degeneration market size from 2020 to 2034 segmented by seven major markets. The report also offers current Age Related Macular Degeneration therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Age Related Macular Degeneration market.

Download sample pages of our report @ https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Age-Related Macular Degeneration Market report:
The Age-related Macular Degeneration market size in seven major markets is segregated into two part, Dry-AMD, and Wet-AMD. As per our analysis and estimation, in 2021, the Age-related Macular Degeneration market size was approximately USD 9,840 million which is further expected to increase by 2034.
As per our estimation, in 2021, the Age-related Macular Degeneration Market Size was approximately USD 1,377 million, and of Wet AMD was approximately USD 8,463 million which is further expected to increase by 2034.
The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Age-related Macular Degeneration.
Upcoming therapy such as OPT-302, KSI-301, RGX-314, AKST4290, and others has the potential to create a significant positive shift in the Wet-AMD market size.

Age Related Macular Degeneration Overview
Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed communities. It is an eye disease that primarily affects older individuals, causing a progressive loss of central vision, which is essential for activities such as driving, reading, recognizing faces, and perceiving the world in color. The progression of AMD leads to a loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thereby compromising their quality of life. Although the exact functional pathogenesis of AMD is not fully understood, recent advancements in genetic technologies have led to the identification of various polymorphisms that have shown unique associations with AMD.

Age-related Macular Degeneration is characterized by the progressive degeneration of the macula, the central part of the retina, resulting in central vision loss. It can be classified into early, intermediate, or late stages based on clinical features such as drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).

AMD can also be categorized as either dry (atrophic or non-neovascular) or wet (exudative or neovascular). In its early stages, AMD rarely causes symptoms, making annual eye examinations crucial for detecting the disease and initiating treatment when it is most effective. During an eye exam, the healthcare provider checks for changes to the retina and macula. Patients may undergo one or more of the following tests:

- Ophthalmoscopy: Examination of the retina using a special magnifying lens.
- Optical Coherence Tomography (OCT): A non-invasive imaging test that provides detailed cross-sectional images of the retina.
- Fundus Photography: Taking pictures of the retina to document changes over time.
- Fluorescein Angiography: A diagnostic test that involves injecting a dye into the bloodstream to highlight blood vessels in the retina and detect abnormalities.

Early detection and management of AMD are key to slowing its progression and preserving vision. Treatment options for AMD include antioxidant vitamins and minerals, anti-VEGF (Vascular Endothelial Growth Factor) therapies, and in some cases, laser therapy. These treatments aim to slow the progression of the disease and maintain the patient's quality of life.
Request for a sample report: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Age Related Macular Degeneration Epidemiological Insights
In the year 2021, the total Age-related Macular Degeneration prevalent cases were approximately 51,743,361 in the 7MM, which might increase at a CAGR of 1.6% by 2034.
The US accounted for approximately 17,282,569 Age-related Macular Degeneration prevalent cases in the year 2021.
In EU-5 countries the highest number of Age-related Macular Degeneration prevalent cases was observed in Germany with 7,850,793 cases in the year 2021, followed by France.
Among the 7MM, Japan accounted for approximately 21% prevalent cases of AMD in the year 2021.
In the year 2021, the total diagnosed cases of AMD were approximately 38,807,521 cases in the 7MM. The highest number of cases were diagnosed in the US.
In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple folds by 2034.
In the epidemiology model, the total age-specific cases of AMD (Dry-AMD, and Wet-AMD), are divided into age groups 50-59 years, 60-69 years, 70-79 years, and ≥80 years respectively. As per the estimates by DelveInsight, the total age-specific cases of AMD are expected to increase during the forecasted period of 2022-2034.
In the US, the total diagnosed cases of dry AMD by age distribution were 2,175,435; 3,380,209; 3,495,783; and 2,614,307 cases for the age group 50-59 years, 60-69 years, 70-79 years, and ≥ 80 years in 2021.

Age-related Macular Degeneration Marketed Drugs
Eylea (aflibercept): Regeneron Pharmaceuticals
Eylea developed by Regeneron is used to treat wet-AMD. It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Eylea is the brand name for the drug called aflibercept. VEGF, a naturally occurring protein in the body triggers angiogenesis, however, in wet-AMD it is associated with abnormal blood vessel growth which causes edema leading to vision loss. Eylea blocks the growth of abnormal blood vessels in the back of the eye.
At present Regeneron is conducting phase III trials to explore less frequent dosing intervals of Eylea. It is evaluating the drug for a higher dose of 8mg in wet-AMD patients after phase II trials met its primary endpoint.
Beovu (brolucizumab): Novartis
Beovu (brolucizumab) is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.
Beovu is the first FDA-approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.
Download sample pages @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Age Related Macular Degeneration Market Outlook
Age-related Macular Degeneration (AMD) is a chronic, progressive, and severe disease affecting the central retina and is the leading cause of irreversible blindness in the Western world and Asia-Pacific countries. Currently, up to 8.7% of the worldwide population has AMD. The wet form of the disease is responsible for more than 90% of the severe central visual acuity (VA) loss associated with AMD.

The introduction of anti-VEGF intravitreal injections has revolutionized the management of wet AMD, effectively blocking the pathophysiological process of AMD, restoring retinal morphology, and maintaining its function. In recent years, anti-VEGF injections have become the standard treatment for wet AMD, providing better results than previous options such as photodynamic therapy (PDT) and laser photocoagulation. Drugs like Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab) have been effective in achieving a rapid resolution of exudative signs in most patients. Additionally, Faricimab and Susvimo have recently been approved for the treatment of wet AMD.

At present, the therapeutic landscape for dry AMD lacks any approved treatment, and there is a substantial unmet need for therapies to slow its progression. The pathophysiology of dry AMD is poorly understood, and the failure to reach primary outcomes in some cases may be linked to the advanced stage of the disease rather than a lack of action on appropriate targets. The forecast model does not include other therapy options, as DelveInsight's analysis does not consider procedures and lifestyle management therapy options for predicting the market size in the 7MM countries. The market size solely focuses on the revenue generated by the pharmacological treatment of AMD.

Promising Therapies in the Age Related Macular Degeneration Pipeline
Eylea (aflibercept)
Beovu (brolucizumab)
Lucentis (ranibizumab)
OPT-302
KSI-301
RGX-314
Danicopan (ALXN2040)
EG-301
And others
Discover more about Age Related Macular Degeneration therapies in the pipeline @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Age Related Macular Degeneration Market
Regeneron Pharmaceuticals
Novartis
Roche
Opthea Limited
Kodiak Sciences Inc.
Regenxbio
Alexion Pharmaceuticals
AstraZeneca
Evergreen Therapeutics
And others
To understand key companies related to the Age Related Macular Degeneration Market, get a snapshot of the Age Related Macular Degeneration Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Age Related Macular Degeneration Market Report:
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Age Related Macular Degeneration Companies: Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., Regenxbio, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, and others
Key Age Related Macular Degeneration Pipeline Therapies: Eylea (aflibercept), Beovu (brolucizumab), Lucentis (ranibizumab), OPT-302, KSI-301, RGX-314, Danicopan (ALXN2040), EG-301, and others
Therapeutic Assessment: Age Related Macular Degeneration current marketed and emerging therapies
Age Related Macular Degeneration Market Dynamics: Age Related Macular Degeneration market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Age Related Macular Degeneration Market Access and Reimbursement
Table of Contents:
1. Age Related Macular Degeneration Market Key Insights
2. Age Related Macular Degeneration Market Report Introduction
3. Age Related Macular Degeneration Market Overview at a Glance
4. Age Related Macular Degeneration Market Executive Summary
5. Disease Background and Overview
6. Age Related Macular Degeneration Treatment and Management
7. Age Related Macular Degeneration Epidemiology and Patient Population
8. Patient Journey
9. Age Related Macular Degeneration Emerging Drugs
10. 7MM Age Related Macular Degeneration Market Analysis
11. Age Related Macular Degeneration Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Age Related Macular Degeneration Market Drivers
15. Age Related Macular Degeneration Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.